Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. reported its quarterly results as a clinical-stage biotechnology company focused on GPCR-targeted oral small molecules, powered by its proprietary Native Complex Platform®. For the three months ended June 30, 2026, revenue rose to $26.7 million (from $0.1 million a year earlier), driven entirely by its global collaboration and license agreement with Novo Nordisk A/S, including research services and milestone recognition. For the six months ended June 30, 2026, revenue was $53.3 million.
Research and development expenses increased to $35.1 million in the quarter and $64.7 million year-to-date, reflecting advancement of Septerna’s pipeline, including the Phase 1 trial of SEP-479 and continued platform and program expansion. General and administrative expenses were $8.5 million for the quarter and $18.7 million year-to-date. Net loss narrowed to $13.0 million for the quarter (from $24.8 million) and to $21.7 million for the first half of 2026 (from $46.3 million), aided by higher collaboration revenue and interest income.
Septerna ended June 30, 2026 with $516.5 million in cash, cash equivalents and marketable securities and $140.4 million in deferred revenue related to the Novo collaboration. Management expects this liquidity to fund planned operations at least into 2029. The company also raised $13.8 million of additional equity via an at-the-market program during the period and continues to operate with no debt.
Septerna, Inc. reported second quarter 2026 results and highlighted progress across its GPCR-focused pipeline. Revenue for the quarter ended June 30, 2026 was $26.7M, largely from its Novo Nordisk collaboration, including $14.6M of upfront payment amortization, $0.9M from research milestones and $11.2M for research services. Research and development expenses rose to $35.1M and general and administrative expenses to $8.5M, leading to a net loss of $13.0M, an improvement from a $24.8M loss a year earlier.
Cash, cash equivalents and marketable securities totaled $516.5M as of June 30, 2026, and the company expects this to fund operations at least into 2029. The Phase 1 trial of SEP-479 for hypoparathyroidism is ongoing; observed elimination half-life of roughly three to four days supports once-daily dosing, with SAD/MAD data expected in the first quarter of 2027. Septerna is also evaluating capital-efficient development paths for SEP-631 in mast cell-driven diseases, advancing its TSHR NAM program toward candidate selection, and continuing discovery work and milestones under its global collaboration with Novo Nordisk.
Septerna, Inc. reported that Daniel D. Long, SVP, Drug Discovery, exercised employee stock options covering 3,334 shares of common stock at an exercise price of $2.7600 per share on August 3, 2026, converting derivative awards into common shares.
On the same date he sold 3,334 shares of common stock in two blocks: 1,000 shares at a weighted average price of $33.9756 per share within a $33.39–$34.32 range, and 2,334 shares at a weighted average price of $34.6805 per share within a $34.43–$35.04 range. These sales were effected pursuant to a Rule 10b5-1 sales plan adopted on March 20, 2026. Related options vest in 48 equal monthly installments starting August 1, 2023 and March 1, 2024, subject to continued service.
Septerna, Inc. President and COO Elizabeth Bhatt reported transactions in company equity on July 15, 2026. She exercised stock options to acquire 4,000 shares of common stock at $6.81 per share and, pursuant to a Rule 10b5-1 sales plan adopted on October 20, 2025, completed a sale transaction of 4,000 shares of common stock at a weighted average price of $33.9935 per share, with individual sale prices ranging from $33.49 to $34.24. Following these transactions, she directly held 174,209 shares of common stock and 80,911 stock options (right to buy) with an exercise price of $6.81 per share, expiring on September 22, 2034.
Septerna, Inc. senior vice president of drug discovery Daniel D. Long reported an exercise-and-sell transaction in company stock. On July 1, 2026, he exercised stock options to acquire 3,333 shares of common stock at $2.76 per share and sold 3,333 shares in open-market transactions.
The sales occurred at weighted average prices of $34.0964 and $34.8141, with actual sale prices ranging from $33.49 to $35.10. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by Long.
Septerna, Inc. reported a Form 4 transaction showing a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036.
The options were granted to Dr. Simson and vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual stockholder meeting, subject to continued service. Under Dr. Simson’s arrangement with RA Capital Management, the option is held for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund III LP, and any net cash or stock from exercise will offset advisory fees owed to RA Capital’s adviser entities. The reporting persons disclaim beneficial ownership of the option and underlying shares except for any pecuniary interest.
Septerna, Inc.’s Chief People Officer Samira Shaikhly reported a combined option exercise and share sale. She exercised stock options to acquire 2,178 shares of Common Stock at $6.81 per share, then sold 2,178 shares at $35.18 per share in an open-market transaction.
The filing notes the sale was made under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025. Following these transactions, she holds 793 Common Stock shares and 20,865 stock options directly.
Septerna, Inc. director Abraham Bassan reported receiving a grant of stock options as part of his compensation. He was awarded options covering 15,000 shares of common stock at an exercise price of $37.34 per share, expiring on June 25, 2036.
These options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders, as long as he continues serving the company through that vesting date. After this grant, his reported derivative holdings in this filing consist of these 15,000 options.
Septerna, Inc. director Shalini Sharp received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036. They vest in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, subject to her continued service. Following this compensation grant, she holds 15,000 derivative securities directly.